- Home
- BBBY vs RIGL Comparison
BBBY vs RIGL Comparison
Compare BBBY & RIGL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | BBBY | RIGL |
|---|---|---|
| Founded | 1971 | 1996 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 573.5M | 537.6M |
| IPO Year | N/A | 2000 |
Fundamental Metrics
Financial Performance| Metric | BBBY | RIGL |
|---|---|---|
| Price | $6.08 | $44.22 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 5 |
| Target Price | $8.00 | ★ $43.20 |
| AVG Volume (30 Days) | ★ 1.8M | 654.6K |
| Earning Date | 10-27-2025 | 11-04-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 2698.26 |
| EPS | N/A | ★ 6.20 |
| Revenue | ★ $1,074,337,000.00 | $282,076,000.00 |
| Revenue This Year | N/A | $65.53 |
| Revenue Next Year | $5.03 | $0.22 |
| P/E Ratio | ★ N/A | $7.00 |
| Revenue Growth | N/A | ★ 79.13 |
| 52 Week Low | $3.54 | $14.63 |
| 52 Week High | $12.65 | $52.24 |
Technical Indicators
Market Signals| Indicator | BBBY | RIGL |
|---|---|---|
| Relative Strength Index (RSI) | 41.98 | 52.32 |
| Support Level | $5.68 | $39.60 |
| Resistance Level | $6.79 | $49.96 |
| Average True Range (ATR) | 0.39 | 3.61 |
| MACD | 0.14 | -0.77 |
| Stochastic Oscillator | 47.73 | 33.47 |
Price Performance
Historical ComparisonAbout BBBY Bed Bath & Beyond Inc.
Bed Bath & Beyond Inc is an ecommerce-focused retailer with an affinity model that owns or has ownership interests in various retail brands, offering a comprehensive array of products and services that enable its customers to enhance everyday life through quality, style, and value. The Company currently owns Bed Bath & Beyond, Overstock, buybuy BABY, and other related brands and websites as well as a blockchain asset portfolio.
About RIGL Rigel Pharmaceuticals Inc.
Rigel Pharmaceuticals Inc develops small-molecule drugs for autoimmune, cancer-related, and viral diseases. The firm's primary drug is an oral rheumatoid arthritis drug candidate that has been licensed to AstraZeneca. Astra has taken overall responsibility for developing and marketing the drug and will pay Rigel royalties and milestone payments. Its pipeline product includes TAVALISSE (fostamatinib disodium hexahydrate) tablets, the only oral spleen tyrosine kinase (SYK) inhibitor, Fostamatinib, R289, R552, R835, DS-3032, THF-beta Inhibitors, and AZD0449- Inhaled JAK Inhibitor.